ClinConnect ClinConnect Logo
Search / Trial NCT01117051

Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation

Launched by SHIRE · May 4, 2010

Trial Information

Current as of June 23, 2025

Terminated

Keywords

Opioid Induced Constipation/Prucalopride Chronic Non Cancer Pain Subjects With Chronic Non Cancer Pain Suffering From Oic

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion criteria to be assessed at screening:
  • 1. Male or non-pregnant, non-breast-feeding female outpatient ≥18 years.
  • 2. Has chronic pain of any aetiology (except cancer pain) requiring daily maintenance treatment with opioids;has been on stable daily opioid dose during at least the previous 2 weeks; and is expected to remain on stable daily dose of opioids for at least 15 weeks after Visit 1.
  • 3. Subject is suffering from OIC (i.e. secondary to chronic opioid use).
  • 4. Subject agrees to stop his/her laxative treatment and is willing to use rescue medication.
  • Main exclusion criteria to be assessed at screening:
  • 1. Constipation is thought to be drug-induced (except for opioids)
  • 2. Disallowed medication is being used
  • 3. Subject was on chronic therapy for chronic constipation prior to start of opioid therapy
  • 4. Subject is suffering from secondary causes of chronic constipation.

About Shire

Shire, a global biotechnology company, specializes in developing innovative therapies for rare diseases and complex conditions. With a strong commitment to improving the lives of patients, Shire focuses on areas such as hematology, immunology, neuroscience, and genetic disorders. The company is dedicated to advancing clinical research and delivering breakthrough treatments that address unmet medical needs. Through collaboration and a patient-centric approach, Shire strives to enhance health outcomes and empower individuals affected by challenging health conditions.

Locations

Leuven, , Belgium

Patients applied

0 patients applied

Trial Officials

Study Director

Study Director

Takeda

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials